Technology
Health
Biotechnology

uniQure

634

$43.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.55 (-1.24%) As of 10:23 AM EDT today
-$0.55 (-1.24%) Today

Why Robinhood?

You can buy or sell uniQure and other stocks, options, ETFs, and crypto commission-free!

About QURE

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. Read More The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

CEO
Matthew C. Kapusta
Employees
248
Headquarters
Amsterdam, Noord-Holland
Founded
1998
Market Cap
1.92B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
507.21K
High Today
$44.92
Low Today
$43.71
Open Price
$44.14
Volume
24.23K
52 Week High
$82.49
52 Week Low
$36.20

Collections

Technology
Health
Biotechnology
Gene Therapies
2014 IPO
Europe (Non-UK)
Europe

QURE News

ReutersMar 26

BRIEF-Uniqure: Achievement Of Target Patient Dosing In Hope-B Pivotal Trial Of AMT-061 In Hemophilia B

March 26 (Reuters) - Uniqure NV: * UNIQURE ANNOUNCES ACHIEVEMENT OF TARGET PATIENT DOSING IN HOPE-B PIVOTAL TRIAL OF AMT-061 (ETRANACOGENE DEZAPARVOVEC) IN HEM
3

QURE Earnings

-$0.97
-$0.65
-$0.32
$0.00
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected Apr 27

People Also Bought

Sarepta Therapeutics

1,908

$94.06

-0.41%

Sarepta Therapeutics

1,908

$94.06

-0.41%

Viking Therapeutics

50,057

$4.59

+1.39%

CRISPR

29,481

$42.48

+1.58%

Sangamo Therapeutics

7,536

$6.32

-0.32%

You May Also Like

PFIN
BIB
APLT
HYACU
BF.B
DBC
LIVK
JMP
FEO
CSM
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy QURE

Market Price$43.71
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell uniQure stock and options commission-free.
Search
LearnBlogCareersHelpLog InSign Up